RxDoctor Payments Data

Corinna Jewell, PA

Surgical · Reno, NVNPI 1982710349

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,832 of the $3,443 with a category attached, or 82.3%. 15 manufacturers reported payments, led by Boston Scientific at 41.5% of the total. Reporting peaked in 2021 at $1,993 and has fallen 78.8% since, to $423 in 2024.

$3,443in general payments, 2019–2025

Across 67 payments — averaging $51.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Cipla USA Inc.$1K
  • Astellas Pharma US Inc$401
  • AbbVie$138
  • Teleflex LLC$77
  • Coloplast$75
  • plus $229 from 9 others

What the payments were for

  • Travel & lodging$3019%
  • Food & beverage$2,83282%
  • Education$3109%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,443 in reported general payments places this provider in the 80th percentile of 91 surgical providers in Nevada.

See all surgical providers in Nevada

Medicare billing

Part B allowed, 2024
$113,234
Medicare patients
629
Services billed
3,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron130$148,321
GemtesaVibegron74$66,683
ElmironPentosan Polysulfate Sodium19$17,890
Tamsulosin Hcl613$12,397
Potassium Citrate ErPotassium Citrate51$5,531
Finasteride301$5,304
Methenamine Hippurate30$3,891
Alfuzosin Hcl ErAlfuzosin Hcl112$3,339
Solifenacin Succinate34$2,387
Testosterone30$2,221
Tadalafil22$1,922
Estradiol21$1,164
Tolterodine Tartrate ErTolterodine Tartrate21$1,151
NitrofurantoinNitrofurantoin Macrocrystal20$907
Doxazosin Mesylate37$900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$401$148,321130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 91 surgical providers in Nevada.

Other surgical in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →